What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
John B. A. G. Haanen focuses on Internal medicine, Melanoma, Immunology, Oncology and Surgery.
His Clinical trial, Dacarbazine, Adverse effect and Performance status study in the realm of Internal medicine connects with subjects such as Pharmacogenetics.
His work in the fields of Melanoma, such as Vemurafenib, intersects with other areas such as Placebo.
His study in Immunology is interdisciplinary in nature, drawing from both Cytotoxic T cell and Cancer.
His research on Oncology also deals with topics like
- Nivolumab and Interim analysis most often made with reference to Ipilimumab,
- Tremelimumab that connect with fields like Temozolomide, Talimogene laherparepvec and Pembrolizumab.
His work carried out in the field of Surgery brings together such families of science as Binimetinib, Cobimetinib and Hazard ratio.
His most cited work include:
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. (10003 citations)
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (1975 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Melanoma, Immunology and Immunotherapy.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Surgery.
His Oncology research is multidisciplinary, incorporating elements of Advanced melanoma, Clinical trial, Phases of clinical research, Targeted therapy and Metastasis.
In the field of Melanoma, his study on Vemurafenib and Dabrafenib overlaps with subjects such as Stage IIIC.
His Immunology research focuses on Cytotoxic T cell and how it connects with Major histocompatibility complex.
John B. A. G. Haanen works mostly in the field of Ipilimumab, limiting it down to concerns involving Nivolumab and, occasionally, Toxicity and Pembrolizumab.
He most often published in these fields:
- Internal medicine (43.20%)
- Oncology (34.32%)
- Melanoma (28.70%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (43.20%)
- Melanoma (28.70%)
- Oncology (34.32%)
In recent papers he was focusing on the following fields of study:
John B. A. G. Haanen spends much of his time researching Internal medicine, Melanoma, Oncology, Cancer research and Cancer.
As part of his studies on Internal medicine, he frequently links adjacent subjects like Gastroenterology.
His Melanoma research integrates issues from Targeted therapy, Clinical trial, Cohort and Systemic therapy.
The Oncology study combines topics in areas such as Pembrolizumab, Immunotherapy, Toxicity and Confidence interval.
His Cancer research research includes elements of Cytotoxic T cell, Cytokine, Immune system and T-cell receptor.
Many of his studies on Ipilimumab involve topics that are commonly interrelated, such as Nivolumab.
Between 2019 and 2021, his most popular works were:
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. (113 citations)
- Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry (34 citations)
- Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. (28 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Oncology, Cancer, Melanoma and Ipilimumab.
John B. A. G. Haanen regularly ties together related areas like Viral load in his Internal medicine studies.
He has included themes like Prospective cohort study, Hepatitis B virus and Hazard ratio in his Oncology study.
John B. A. G. Haanen combines subjects such as Epidemiology, Cohort study, Vaccination, Lung cancer and Pandemic with his study of Cancer.
He interconnects T cell, Long term follow up and Complete response in the investigation of issues within Melanoma.
His research integrates issues of Gastroenterology, Blockade, Cutaneous melanoma, Nivolumab and Cohort in his study of Ipilimumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
